1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
(NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%.
The shares' trajectory can be difficult to predict given the uncertainty around the business. And there's a troubling stat that could have you thinking twice about Pfizer and whether it's really worth buying -- especially if you're a growth investor.
The past doesn't predict the future, but it can give investors a good insight into how a stock typically performs. Growth stocks, while they may have a bad year here and there, typically do well over a long period and the better ones usually outperform the broader market.
Source Fool.com
Pfizer Inc. Aktie
Klares Buy-Übergewicht bei der Pfizer Inc. Aktie mit 29 zu 4 Einschätzungen.
Das von der Community festgelegte Kursziel für Pfizer Inc. von 41 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 27.88 €.
